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Removal of cholesterol from peripheral tissues to the
bloodstream via reverse cholesterol transport (RCT)
is a process of major biological importance. Here
we demonstrate that lymphatic drainage is required
for RCT. We have previously shown that hypercho-
lesterolemia in mice is associated with impaired
lymphatic drainage and increased lipid accumulation
in peripheral tissues. We now show that restoration
of lymphatic drainage in these mice significantly
improves cholesterol clearance. Conversely, ob-
struction of lymphatic vessels in wild-type mice
significantly impairs RCT. Finally, we demonstrate
using silencing RNA interference, neutralizing anti-
body, and transgenic mice that removal of choles-
terol by lymphatic vessels is dependent on the
uptake and transcytosis of HDL by scavenger recep-
tor class B type I expressed on lymphatic endothe-
lium. Collectively, this study challenges the current
view that lymphatic endothelium is a passive ex-
change barrier for cholesterol transport and provides
further evidence for its interplay with lipid biology in
health and disease.
INTRODUCTION
Reverse cholesterol transport (RCT) is a multistep process
whereby excess cholesterol is transported by high-density lipo-
protein (HDL) from the peripheral tissues to the liver for excretion
in the bile and feces (Rader et al., 2009; Tall, 2008). The initial and
final steps in RCT, including cholesterol efflux from macro-
phages to extracellular HDL and cholesterol uptake in the liver
for disposal as biliary cholesterol and bile salts, respectively,
have been extensively studied and well characterized. In
contrast, much less information is available on the route bywhich
HDL cholesterol travels from the peripheral tissues to the liver.CSince one of themajor roles of the lymphatic system is to drain
macromolecules from the interstitial space back to the circula-
tion, it is generally assumed that the return of lipoproteins from
the interstitium to plasma may occur primarily via the lymphatic
system, and less so via the venous capillaries (Cooke et al.,
2004). Although several lines of evidence support this scenario,
it has not been directly demonstrated. Analyses of the composi-
tion of animal and human lymph revealed that lymph is rich in
cholesterol and HDL (Nanjee et al., 2001; Reichl, 1990; Roheim
et al., 1990) and the composition in lipoproteins varies with
changes in lymphatic flow (Cooke et al., 2004). In amore detailed
study of the different lipoproteins fractions in human lymph, it
was shown that the lymph concentration of HDL cholesterol
was 30% greater than that of blood, and the authors estimated
a whole-body reverse cholesterol transport rate of 344 mg/day
via the lymph (Nanjee et al., 2001). However, the lymph/plasma
concentration ratios of lipoprotein reported by Nanjee et al.
should be considered with care, as they contradict data by other
groups (Sloop et al., 1987). Analysis of the transport of labeled
cholesterol after intravenous injection in humans indicated that
some of the cholesterol detected in lymph was derived from a
pool of tissue cholesterol (Reichl et al., 1973).
Clinical and experimental studies have linked lymphatic
function to lipid metabolism and transport (Dixon, 2010).
Obstructions of lymphatic vessels in mouse not only account
for architectural tissue changes, edema, and infiltration of
immune cells, but also abnormal lipid accumulation in the skin
(Rutkowski et al., 2006). In addition, massive lipid deposits
are also evident in the edematous tissues of patients with lym-
phedema (Schirger et al., 1962). Recently, we demonstrated
that hypercholesterolemic apolipoprotein E-deficient (apoE/)
mice develop lymphatic dysfunction and exhibit peripheral
edema (Lim et al., 2009). This edema was associated with
marked lipid accumulation. These observations led us to pro-
pose that hypercholesterolemia may impair lymphatic function,
and this loss of function could further exacerbate the accumula-
tion of cholesterol and worsen edema in the peripheral tissues.
However, the question as to whether restoration of lymphatic
function in apoE/ mice would ameliorate the accumulation of
lipids and edema remained to be addressed.ell Metabolism 17, 671–684, May 7, 2013 ª2013 Elsevier Inc. 671
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vessel structure and function, our current knowledge of the basic
mechanisms involved in lymphatic lipid transport is relatively
poor. The entry of fluid,macromolecules, and cellsmainly occurs
throughout initial lymphatic vessels, which are blind-ended ves-
sels lacking smooth muscle cells via openings between button-
like junctions (Baluk et al., 2007). The initial lymphatic vessels
converge into larger collecting vessels that exhibit smooth
muscle cells on their outer wall to actively pump the lymph
back to the blood circulation (Muthuchamy and Zawieja, 2008).
Maintenance of initial and collecting vessel structure is critical
for lymphatic function (Lim et al., 2009; Petrova et al., 2004).
Although the prevailing view is that lymphatic vasculature plays
a passive role in the uptake of fluid, macromolecules, and cells,
increasing evidence suggests a more active role of lymphatic
vessels than previously anticipated. Recent studies on the
mechanisms of leukocyte entry through lymphatics revealed
the involvement of specialized entry sites (Baluk et al., 2007;
Pflicke and Sixt, 2009) and molecules expressed on the
lymphatic endothelium including adhesion molecules and che-
mokines (Johnson and Jackson, 2010; Schumann et al., 2010;
Tal et al., 2011). Thus, these findings raise the possibility that
the removal of cholesterol by lymphatic vessels may also be a
specific and active process, and, if confirmed, this would imply
that the lymphatic endothelium may be able to control the
composition of lipoprotein in tissue fluid and lymph.
In light of the emerging significance of lymphatic vessel in lipid
metabolism and transport in health and disease, we decided to
evaluate the contribution of lymphatic vessels in the clearance
of lipoproteins from peripheral tissues and to identify the media-
tors involved in this process.
RESULTS
Reversing Dyslipidemia in apoE–/– Mice Restores the
Structure and Function of Lymphatic Vessels
We hypothesized that reduction of circulating cholesterol levels
and increase of HDL levels in apoE/ mice may restore
lymphatic structure and function. To address this, we measured
the effect of the reduction of plasma cholesterol levels in
apoE/mice by using the cholesterol-lowering drug ezetimibe,
which blocks dietary and biliary cholesterol absorption from the
intestine. Consistent with other reports (Davis et al., 2001;
Kuhlencordt et al., 2009), total plasma cholesterol levels in
apoE/ mice fed a high-fat diet were significantly reduced by
4 weeks of ezetimibe treatment and maintained below 600 mg/
dl throughout the whole duration of treatment regime (Figures
S1A–S1C available online). In contrast, vehicle-treated apoE/
mice had grossly elevated cholesterol levels (>2,000 mg/dl), as
we reported previously (Lim et al., 2009) (Figure S1A). Treatment
with ezetimibe also markedly increased plasma HDL cholesterol
in apoE/ mice to levels similar to those in wild-type (WT) mice
(Figure S1B). Ezetimibe did not have any effect on total choles-
terol or HDL cholesterol in WT mice (Figures S1A and S1B). In
the following experiments, vehicle-treated WT mice were used
as control for comparison with vehicle-treated apoE/ mice.
In agreement with our previous study (Lim et al., 2009), micro-
scopic analysis of ear skin whole mount with lymphatic vessel
endothelial hyaluronan receptor 1 (LYVE-1) showed hyperplasic672 Cell Metabolism 17, 671–684, May 7, 2013 ª2013 Elsevier Inc.initial lymphatic vessels in vehicle-treated apoE/ mice (Fig-
ure 1A). With ezetimibe treatment, initial lymphatic vessels
were substantially less dilated (Figure 1B). Consistent with previ-
ous reports (Petrova et al., 2004; Lim et al., 2009), collecting ves-
sels in WT mice downregulated LYVE-1 and were endowed with
smooth muscle cells, whereas LYVE-1 remained highly ex-
pressed and smooth muscle cell coverage was sparse on col-
lecting lymphatic vessels from vehicle-treated apoE/ mice
(Figure 1C). However, amelioration of dyslipidemia in these
mice restored the identity of collecting vessels (Figure 1C). We
next investigated the functionality of these vessels. Evans blue
dye lymphangiography is a standard method for assessing
lymphatic function (Danussi et al., 2008). After intradermal injec-
tion of Evans blue dye into the ear rim, fine distinct lymphatic
vessels were visualized in ezetimibe-treated apoE/ mice as
observed in WT mice, demonstrating that these lymphatic ves-
sels are functional (Figure 1D). In contrast, vehicle-treated
apoE/ mice showed markedly dilated lymphatic vessels, and
Evans blue dye extravasated from these dilated vessels (Fig-
ure 1D). As an alternative measure of lymphatic function, we
analyzed the capacity of lymphatic vessels to transport dendritic
cells from the peripheral tissue to the draining lymph nodes
(LNs). Consistent with our previous report (Angeli et al., 2004),
the migration of skin dendritic cells in apoE/ was significantly
impaired compared to WT mice (Figure 1E), but it was improved
by ezetimibe treatment (Figure 1E).
Amelioration of Lymphatic Drainage in apoE–/– Mice
Reduces Cholesterol Accumulation in Tissues
We next determined whether this improved lymphatic drainage
in ezetimibe treated apoE/ mice had some consequences
on the peripheral edema and lipid accumulation observed in
apoE/ mice (Lim et al., 2009; van Ree et al., 1995). Macro-
scopic examination of the footpad revealed exaggerated
swelling in vehicle-treated apoE/ mice compared to WT
mice (1.942 ± 0.028 mm versus 1.603 ± 0.019 mm, n = 11–16,
p < 0.0001), and ezetimibe treatment ameliorated this swelling
(1.630 ± 0.021 mm, n = 11–16, p < 0.0001) (Figure 2A). Further-
more, oil red O staining and measure of total cholesterol in
footpads demonstrated that this attenuated swelling in ezeti-
mibe-treated apoE/ mice was, in part, associated with a
decrease in the neutral lipid and cholesterol deposition in these
tissues (Figures 2B and 2C). As also reported in several animal
models of hypercholesterolemia (Armstrong et al., 1986; Ishiba-
shi et al., 1994; van Ree et al., 1995), the skin of apoE/ mice
exhibited accumulation of macrophages and xanthomas, which
consist of cholesterol-rich deposits, particularly rich in macro-
phages (Figures 2B–2D). Notably, total macrophages (Figure 2D)
and lipid-laden macrophages (Figure 2E) were less abundant
in ezetimibe-treated apoE/ mice with improved lymphatic
drainage. Altogether, these findings suggest that reduction of
plasma total cholesterol and increase of HDL in apoE/ mice
restored lymphatic function and, hence, lipid, fluid, and leuko-
cyte clearance from peripheral tissues. Similar results were
obtained in another murine model of hypercholesterolemia and
atherosclerosis, the Ldlr/mice, further supporting the physio-
logical relevance of our observations (Figure S2).
In an effort to identify the mediators responsible for the
defects in lymphatic vessels from apoE/ mice, we performed
Figure 1. Restoration of Lymphatic Vessel Structure and Function in
apoE–/– Mice by Reducing Hypercholesterolemia
(A–C) LYVE-1 immunostaining was examined in ear whole mounts from WT
and apoE/mice after 12 weeks of treatment with vehicle (NT) or ezetimibe (T)
(A). The diameter of initial lymphatic vessels was quantified with n = 6 and **p <
0.005 (B). Ear whole mounts were stained with LYVE-1, smooth muscle actin
(SMA), and podoplanin for identification of collecting lymphatic vessels (C).
Arrows indicate smooth muscle cells. Smooth muscle actin also stained for
blood vessels (arrowheads). Images are representative of two repeated ex-
periments, and n = 4 per group (A and C). Scale bars represent 400 mm in (A)
and 250 mm in (C).
(D and E) Evans blue lympahgiography was performed (D). Similar results
were obtained in three repeated experiments. Scale bars represent 1.0 mm.
For quantification of DC migration to draining LNs, mice received epicuta-
neous FITC and the percentage of migrated FITC+CD11c+ DCs in draining LNs
was determined (E). Data are pooled from two independent experiments with
n = 7–13.
**p < 0.005. Data are shown as mean ± SEM. See also Figure S1.
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Cquantitative real-time PCR analyses on skin from vehicle-treated
WT and apoE/mice and ezetimibe-treated apoE/mice. This
analysis revealed that the expression of VEGF-C, ANG-2, and
FOXC2 (Tammela and Alitalo, 2010), which are important factors
to maintain lymphatic vasculature, was significantly reduced in
apoE/ vehicle-treated mice (Figure 3A). No differences were
observed for VEGF-A, VEGF-D and bFGF. Lowering cholesterol
in apoE/ mice with ezetimibe significantly increased VEGF-C,
ANG-2, and FOXC2 expression to levels similar to WT mice (Fig-
ure 3A). Because treatment with VEGF-C has been shown in
other models to improve lymphatic drainage (Szuba et al.,
2002; Breslin et al., 2007), we investigatedwhether local injection
of VEGF-C could ameliorate lymphatic function and cholesterol
accumulation in apoE/ mice. To evaluate lymphatic function
in a more quantitative manner than Evans blue lymphangiog-
raphy, we measured the transport of fluorescein isothiocyanate
(FITC) dextran from the footpad to the draining LN. This assay
confirmed the dysfunctional lymphatic vessels in apoE/ mice
(Figure 3B) and demonstrated that VEGF-C treatment signifi-
cantly improved lymphatic function in apoE/mice (Figure 3C).
Furthermore, amelioration of lymphatic function in apoE/mice
significantly reduced the accumulation of cholesterol in the
footpads, and this effect did not result from reduced hypercho-
lesterolemia (Figures 3D and 3E). These data showed that
improvement of lymphatic function without affecting hypercho-
lesterolemia can be sufficient to reduce cholesterol accumula-
tion in apoE/ mice.
Lymphatic Drainage Is Required for Cholesterol HDL
Transport from Peripheral Tissue into Blood Circulation
The close relationship between lymphatic drainage dysfunction
and lipid accumulation in peripheral tissue observed in apoE/
mice raised the possibility that, under physiological conditions,
RCT may depend on lymphatic vessels and that adequate
lymphatic transport may be necessary to limit excessive accu-
mulation of cholesterol in tissues. To address this possibility,
we tested whether impaired lymphatic drainage would affect
RCT. We adapted and recapitulated a RCT model using fluores-
cence-labeled cholesterol instead of radiolabeled cholesterol.
First, we confirmed in vitro that this fluorescent cholesterol
was efficiently effluxed from macrophages in presence of HDL
and that this fluorescent-cholesterol efflux was also mediated
by ATP-binding cassette transporter A1 (ABCA1) using probucol
(Figures S3A and S3B). We also confirmed in vivo that the fluo-
rescent cholesterol was transported into the plasma and feces
after intraperitoneal injection of macrophages loaded with the
fluorescent cholesterol as described in original studies using
radiolabeled cholesterol (Figure S3C) (Wang et al., 2007; Zhang
et al., 2003). Next, we evaluated in vivo the levels of fluorescence
after the deposition of fluorescent-cholesterol-loaded macro-
phages in the footpad. Consistent with previous studies using
radiolabeled cholesterol, we were able to detect fluorescent
cholesterol in plasma, liver, and feces of WT mice (Figure 4). A
significant amount of fluorescent cholesterol was removed
from the site of injection by 48 hr (Figure 4A) andwas foundwithin
the LN draining the site of injection and in the efferent lymph as
soon as 6 hr (Figures 4B and 4C). Fluorescent cholesterol was
only detected in plasma by 12 hr (Figure 4D), 48 hr, and 72 hr
in liver and feces, respectively (Figures 4E and 4F). The plasmaell Metabolism 17, 671–684, May 7, 2013 ª2013 Elsevier Inc. 673
Figure 2. Diminution of Peripheral Lipid Accumulation in apoE–/–
Mice with Improved Lymphatic Drainage
(A) Compared to those ofWT and T apoE/mice, the footpads of NT-apoE/
mice were edematous (arrowheads). The scale bar represents 2 mm.
(B) Oil red O staining of footpad skin sections demonstrated that edema in NT
apoE/micewas associatedwith increased lipid accumulation. The scale bar
represents 200 mm.
(A and B) Images are representative of two repeated experiments, and n = 4
per group.
(C) Total cholesterol levels were analyzed in footpads fromNTWT and apoE/
mice and T apoE/mice. Data are expressed as mean ± SEM with n = 11–16
per group. ***p < 0.0005.
(D and E) Footpad skin sections from WT, NT, and T apoE/ mice were
stained for CD68 (D). Costaining of CD68 with oil red O showed more mac-
rophages loaded with lipids (arrowheads) in NT apoE/mice compared to NT
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674 Cell Metabolism 17, 671–684, May 7, 2013 ª2013 Elsevier Inc.fluorescent cholesterol was primarily in HDL fraction (Fig-
ure S3D). Finally, we evaluated RCT in WT mice in which
lymphatic drainage was altered by cutting of afferent lymphatic
vessels draining from the footpad to thepopliteal LN (Figure S3E).
Notably, the clearance of cholesterol from the site of cholesterol-
loaded macrophage deposition and its transport to lymph,
blood, liver, and feces was markedly impaired in mice with
excised lymphatic vessels (Figures 4G–4K). Impairing lymphatic
drainage in WT mice impaired not only RCT of fluorescent
cholesterol but also the transport of tissue cholesterol (Figure 4L).
However, this effect was not accompanied by changes in plasma
cholesterol (Figure 4L). Because apoE/ mice exhibit impaired
lymphatic transport, we tested whether RCT of fluorescent
cholesterol may be affected in these mice. The transport of fluo-
rescent cholesterol from the site of its deposition to plasma and
liver was markedly compromised in apoE/ mice (Figures 4M–
4R). However, ameliorating lymphatic function in apoE/ by
either ezetimibe (Figures 4M–4O) or VEGF-C (Figures 4P–4R)
treatment significantly improved RCT of fluorescent cholesterol.
Because HDL acts as an extracellular acceptor of cholesterol
andmediates the transport of excess cholesterol from peripheral
tissues to the liver, we verified that lymphatic vessels could
transport HDL. Consistent with reports in human lymph (Cooke
et al., 2004; Nanjee et al., 2001), we were able to detect the
presence of HDL in lymph canulated from the cisterna chyli of
8-week-old WT mice. HDL concentration in lymph (29.48 ±
6.50 mg/dl, n = 5) was similar to HDL concentration in plasma
(35.95 ± 1.52 mg/dl, n = 5). Next, we examined the transport of
Dil-labeled HDL after subcutaneous injection into the rear
footpad of WT mice. FITC-labeled dextran was coinjected with
Dil-HDL to visualize lymphatic vessels (Figure 5A). Fluorescent
images revealed that Dil-HDL colocalized with FITC-dextran
and drained from the footpad to the popliteal LN via afferent
lymph then into the next proximal iliac LN via efferent lymph
and finally into the thoracic duct which drains to the blood circu-
lation (Figure 5A). More importantly, the clearance of HDL from
the footpad was significantly impaired (Figure 5B), and its subse-
quent accumulation in the draining LN and plasma was reduced
by 90% and 80%, respectively, in mice with surgically impaired
lymphatic drainage compared to sham-operated animals (Fig-
ures 5C and 5D). Improvement of lymphatic drainage in apoE/
mice by ezetimibe or VEGF-C treatment significantly ameliorated
the transport of Dil-HDL (Figure 5E and 5F).
Lymphatic Endothelial Cells Express Functional HDL
Transporters
The finding that HDL can be transported in vivo by lymphatic
vessels raised the possibility that the entry of cholesterol into
lymphatics may be mediated by HDL-associated transporters
(Tall, 2008) including SR-BI, ABCA1, and ABCG1. Quantitative
real-time PCR analysis of the expression of these transporters
on the murine lymphatic endothelial cell line, SV-LECs, (Ando
et al., 2005) revealed that SR-BI and ABCA1, but not ABCG1,
were expressed in SV-LECs (Figure 6A). The expression levelsWT and T-apoE/ mice (E). Similar findings were observed in two indepen-
dent experiments, and n = 2 per group. Scale bars represent 200 mm.
See also Figure S2.
Figure 3. Improved Lymphatic Transport and Attenuated Peripheral Lipid Accumulation in apoE–/– Mice Treated with VEGF-C
Total mRNA extracted from the ear skin of vehicle (NT)- or ezetimibe (T)-treated WT and apoE/mice were evaluated by quantitative real-time PCR (A). Results
collected from two independent experiments (n = 6). WT and apoE/ (B) or vehicle- and VEGF-C-treated apoE/ (C) FITC-dextran content in draining LNs was
evaluated 10 min after injection in footpad. Total cholesterol levels were measured in the plasma (D) and footpads (E) from vehicle- and VEGF-C-treated apoE/
mice. Data expressed as mean ± SEM with n = 4–10 per group. *p < 0.05, **p < 0.005, and ***p < 0.0005.
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Figure 4. Inhibition of RCT inMice with Impaired
Lymphatic Drainage
(A–K) WT mice received footpad injections of fluores-
cent-cholesterol-loaded macrophages. Content in
fluorescent cholesterol was evaluated 5 min and 6, 12,
24, and 48 hr after injection in footpad (A), LN (B), lymph
(C), plasma (D), and liver (E). Feces were collected
continuously from 0–24, 24–48, and 48–72 hr for
fluorescent-cholesterol measurements (F). Twenty-one
days after surgery (see Figure S3E), sham and surgical-
operated animals received fluorescent-cholesterol-
loaded macrophages. Fluorescent cholesterol was
evaluated at 48, 12, 24, 48, and 48–72 hr in footpad (G),
lymph (H), plasma (I), liver (J), and feces (K), respec-
tively. Data are expressed as the percentage of
fluorescent cholesterol relative to total fluorescent
cholesterol detected at 5 min in the footpad (site of
injection).
(L) Total cholesterol content in the plasma and footpad
from sham and surgical-operated mice were analyzed.
(M–R) RCT was assessed in apoE/mice treated with
vehicle, ezetimibe (M–O) or VEGF-C (P–R) as described
in Figures 1 and 3 by measurement of fluorescent
cholesterol in footpad (M and P), plasma (N and Q), and
liver (O and R).
Data were collected from two to six independent ex-
periments with n = 5–12 per group and are shown as
mean ± SEM; *p < 0.05, **p < 0.005, ***p < 0.0005. See
also Figure S3.
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Figure 5. Impaired Transport of HDL from
Peripheral Tissues by Obstruction of
Lymphatic Drainage
(A) Transport of Dil-HDL from footpad to thoracic
duct via lymphatic vessels was assessed. For
visualization of lymphatic vessels, FITC-dextran
was also coadministrated with Dil-HDL. Dil-HDL
was transported from the footpad to the popliteal
LNs via afferent (i) then efferent (ii) lymphatic
vessel, into the next proximal iliac LNs (iii), and,
subsequently, into the thoracic duct (iv). The same
findings were observed in three repeated experi-
ments. Scale bars represent 500 mm.
(B–D) Lymphatic vessel flow was disrupted in WT
mice, and 12 days after, Dil-HDL was subcutane-
ously injected in the footpad. One hour later,
footpads (B), LNs (C), and plasma (D) were
collected for measurement of Dil-HDL. Data are
expressed as Dil-HDL relative to sham-operated
groups and as mean ± SEM and pooled from two
independent experiments with n = 6–12 per group.
***p < 0.0005.
(E and F) Quantification of Dil-HDL transport to
LNs was performed on NT and T ezetimibe
apoE/ (E) or vehicle- and VEGF-C treated
apoE/ (F) mice. Data were collected from two
independent experiments with n = 5–7. *p < 0.05.
Data are shown as mean ± SEM.
Cell Metabolism
Lymphatics Are Critical for Cholesterol Clearanceof SR-BI and ABCA1 in LECs were similar to RAW macrophage
cell lines, which served as positive control (Lorenzi et al., 2008).
Microscopic (Figure 6B) and flow-cytometric (Figure 6C) immu-
nofluorescence analyses for SR-BI and ABCA1 confirmed that
SV-LECs expressed these two HDL transporters at their surface.
Confocal fluorescence microscopy of SV-LECs revealed that
HDLwas internalized by LECs as soon as 10min after incubation
with Dil-HDL, and this was even more apparent at 30 and 60 min
(Figure 6D). Internalization of HDL in LECs was confirmed by the
partial colocalization of vesicles containing Dil-HDL with Alexa
488 transferrin (Figure 6E).
Downregulation of SR-BI expression in SV-LECs but not
ABCA1 by RNA interference significantly impaired HDL uptake,
corresponding to 80% inhibition of HDL uptake (Figure 6F). To
further confirm these results, we measured the effect of a
blocking antibody against SR-BI or a specific chemical inhibitor,
BLT1, on HDL uptake. Incubation with SR-BI antibody inhibited
Dil-HDL uptake by SV-LECs analyzed 10 and 60 min after the
incubationwith Dil-HDL (Figure 6G). A similar effect onHDL inter-Cell Metabolism 17, 671nalization by SV-LECs was observed
after incubation with BLT1 (Figure S4A).
Next, we studied whether HDL can
be transported through a monolayer of
LECs. For this assay, the lipid and apoli-
poprotein components of HDL were
labeled with Dil and Alexa 488, respec-
tively, and this dual-labeled HDL was
added on the top of the SV-LEC mono-
layer. A significant amount of Dil-HDL
and Alexa-488-HDL was transported
1 hr after incubation with dual labeled
HDL into the bottom compartment at37C (Figure 6H). In contrast, the transport of Dil-HDL and
Alexa-488-HDL was markedly diminished at 4C, a temperature
known to prevent internalization (Rohrer et al., 2009), suggesting
HDL is transcytosed through LECs (Figure 6H). Pretreatment
of SV-LECs with anti-SR-BI blocking antibody significantly in-
hibited the transport of dual labeled HDL through LECmonolayer
(Figure 6I) but did not affect the transport of FITC-dextran (Fig-
ure 6J). Expression of SR-BI, internalization of HDL, and involve-
ment of SR-BI in mediating HDL transport through a monolayer
of LECs were also observed in human primary dermal LECs,
supporting the relevance of our findings in human physiology
(Figures S4B–S4E).
HDL Transport by Lymphatic Vessels Involves SR-BI
Here, we evaluated in vivo the relevance of our in vitro findings.
Consistent with our observations in SV-LECs, fluorescent micro-
scopic and flow-cytometric analyses revealed the expression of
SR-BI on podoplanin+ lymphatic vessels from skin of WT mice
(Figures 7A and 7B). Then, we went on to test in vivo the effect–684, May 7, 2013 ª2013 Elsevier Inc. 677
(legend on next page)
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Notably, we found that treatment of WT mice with SR-BI block-
ing antibody significantly inhibited the transport of HDL via
lymphatic vessels since the accumulation of fluorescent signal
in LN from SR-BI treated mice was reduced by 75% compared
to untreated animals (Figure 7C). However, blocking SR-BI did
not affect the transport of the macromolecule TRITC-dextran
to the LN (Figure 7C). Finally, we demonstrated that RCT of fluo-
rescent cholesterol in WT mice treated with SR-BI blocking anti-
body was significantly compromised (Figure 7D). That the levels
of fluorescent cholesterol increased at 24 hr and 48 hr in plasma
of SR-BI-antibody-treated mice compared to untreated mice is
consistent with RCT studies in SR-BI-deficient mice reporting
that cholesterol accumulates in the plasma as a result of block-
ing SR-BI mediated transport of cholesterol into the liver (Zhang
et al., 2003). To further confirm these findings, we usedmice with
a targeted null mutation in SR-BI gene. As previously reported
(Rigotti et al., 1997), total cholesterol and HDL levels were
elevated in the plasma of 6- to 8-week-old heterozygous (SR-
BI+/) or homozygous (SR-BI/) mutants compared to age-
matched WT mice (Figures S5A and S5B). Notably, RCT of
fluorescent cholesterol was significantly inhibited in SR-BI/
mice and in a lesser extend in SR-BI+/mice (Figure 7E). Consis-
tent with a previous report (Zhang et al., 2003) and our RCT
results in mice treated with SR-BI-neutralizing antibody, fluores-
cent cholesterol accumulated in plasma at 24 hr and 48 hr in SR-
BI/ mice. Moreover, SR-BI/ mice showed an accumulation
of total cholesterol in skin (Figure 7F). The transport of HDL to
LN by lymphatic vessels was also significantly impaired in SR-
BI+/ and SR-BI/ mice (Figure 7G). However, the deficiency
in SR-BI did not alter the transport of TRITC dextran from the
footpad to the draining LN (Figure 7H). Altogether, our findings
demonstrate for the first time that lymphatic vessel can transport
HDL cholesterol through a mechanism that is, at least in part,
dependent on SR-BI.
DISCUSSION
RCT is necessary to maintain cellular homeostasis and protects
against atherosclerosis (Rader et al., 2009). RCT is initiated when
tissue macrophages efflux cholesterol to extracellular HDLs.
This step is tightly regulated through the action of ABCA1,Figure 6. In Vitro HDL Uptake by Lymphatic Endothelial Cells
(A) Gene expression of ABCA1, ABCG1, and SR-BI was analyzed in SV-LECs a
independent experiments are expressed as gene expression relative to GAPDH.
(B) CD68+ RAWmacrophages and SV-LECs (as identified by lymphatic marker po
experiments. Scale bars represent 20 and 50 mm.
(C) Surface expression of SR-BI and ABCA1 was analyzed by flow cytometry on
(D) Dil-HDL uptake by SV-LECs was quantified 10 min, 30 min, and 1 hr after inc
(E) SV-LECswere incubatedwith Dil-HDL for 1 hr followed by Alexa 488 transferrin
The scale bar represents 20 mm.
(F) SV-LECs were transfected with either small interfering RNA against SR-BI or
expressed as a percentage of fluorescence intensity relative to negative control
(G) SV-LECs were preincubated with blocking SR-BI antibody or control IgG for
inhibited Dil-HDL uptake by SV-LECs. Images are representative of five repeated
(H–J) HDL labeled with Dil and Alexa 488 (H and I) or FITC-dextran (J) was added
LEC inserts pretreated with SR-BI blocking antibody or control IgG at 37C (I and
fluorescencemeasurements. Data were pooled from three to seven inserts, and th
shown as mean ± SEM.
See also Figure S4 and Table S1.
CABCG1, and SR-BI (Tall, 2008). After cholesterol efflux, HDL
cholesterol is transported from the peripheral tissue back into
the blood circulation and then taken up by the liver either directly
via SR-BI or indirectly via low density lipoprotein receptors. In the
final step of RCT, the majority of HDL-derived cholesterol is
removed from the liver by secretion into the bile, after which it
is excreted via the feces (Rader et al., 2009; Tall, 2008). The
routes whereby HDL cholesterol travels from the peripheral tis-
sues back to the circulation are still not well characterized. It
has been suggested previously that RCT is so important biolog-
ically that it may utilize all available routes (Reichl and Miller,
1989). Here, we provide direct evidence that the return of choles-
terol to the plasma can occur via the lymphatic system. We took
advantage of the existence of fluorescence-labeled cholesterol
(Lamant et al., 2006; Sparrow et al., 1999) and HDL to image
in vivo their transport after they have been introduced into the
subcutaneous tissue of healthy animals. This analysis revealed
that both cholesterol and HDL travel from the skin back to the
blood circulation via lymphatic vessels, draining LNs and the
thoracic duct. Impairment of peripheral lymphatic drainage by
surgical excision of afferent lymphatic vessels in WT mice
potently abrogated the transport of fluorescence-labeled HDL
to both draining LNs and plasma, trapping HDL in the peripheral
site of injection. Furthermore, compromise of lymphatic function
in our modified in vivo RCT model also markedly reduced the re-
turn of cholesterol to plasma and liver after cholesterol efflux
from macrophages deposited in subcutaneous tissue. This is,
to our knowledge, the first report to show the pivotal contribution
of lymphatic drainage in the initial step of RCT. In contrast, the
venous capillary system does not seem sufficient to support
the transport of HDL cholesterol back to the circulation, as pre-
viously anticipated (Reichl, 1990, 1994).
Next, we went on to investigate the mechanisms by which
lymphatic vessels transport cholesterol, as they remain poorly
studied despite the recent advances in our knowledge of
lymphatic biology. With the exception of immune cell entry, it is
generally thought that the lymphatic systemmaintains interstitial
fluid homeostasis by allowing passive entry of macromolecules
and fluid through blind-ended openings within the initial
lymphatic vessels (Schulte-Merker et al., 2011). This study, un-
expectedly, challenges this current view by demonstrating that
cholesterol entry into the lymphatic vessels can be a controllednd RAW macrophages by quantitative real-time PCR. Data pooled from three
doplanin) costained for SR-BI and ABCA1. Similar findings were observed in 3
RAW cells and SV-LECs.
ubation of Dil-HDL. ***p < 0.0005.
for 30min. The experiment was repeated two times with the same observation.
ABCA1 or negative control for 7 hr before incubation with Dil-HDL. Data are
and were pooled from three independent experiments.
1 hr followed by incubation with Dil-HDL. SR-BI antibody but not control IgG
experiments (n = 3 per group). The scale bar represents 50mm.
on the top of SV-LECs cultured on inserts at 4C and 37C (H) or on top of SV-
J). After 1 hr, the supernatant from the bottom compartment was collected for
e experiments were repeated at least two times. *p < 0.05, **p < 0.005. Data are
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Figure 7. SR-BI-Mediated Reverse Cholesterol
Transport by Lymphatic Vessels
(A) Skin sections from WT mice were stained for SR-BI
and podoplanin. Arrows indicate a lymphatic vessel. A
similar finding was observed in four repeated experi-
ments. The scale bar represents 50 mm.
(B) Cell suspension from mouse ear dermis was stained
for CD45, podoplanin, CD31, and SR-BI to assess
the expression of SR-BI on LECs (CD45–CD31+
podoplanin+).
(C) WT mice were treated with either SR-BI blocking
antibody or control IgG, and 12 hr later, either Dil-HDL or
TRITC-dextran was injected into the rear footpads.
Draining LNswere collected 1 hr and 10min later for Dil-
HDL and TRITC-dextran, respectively, for evaluation of
the fluorescent tracer. Data are expressed as relative
fluorescent tracer to control IgG and were compiled
from two independent experiments with n = 5–6 per
group. *p < 0.05.
(D and E) Control IgG and SR-BI blocking antibody
treated WT mice (D) or SR-BI+/ and SR-BI/ mice (E)
received footpad injection of fluorescent-cholesterol-
loaded macrophages, and the fluorescent-cholesterol
content was evaluated in footpad, LN, lymph, plasma,
and liver. Data are expressed as the percentage of
fluorescent cholesterol relative to total fluorescent
cholesterol detected at 5 min in the footpad (site of in-
jection) and were collected from two independent ex-
periments with n = 5–8 per group.*p < 0.05, **p < 0.005.
(F) Total cholesterol levels were analyzed in footpads
from WT, SR-BI+/ and SR-BI/ mice. n = 7–14 per
group. ***p < 0.0005.
(G and H) WT, SR-BI+/, and SR-BI/ mice received
Dil-HDL (G) or TRITC-dextran (H) into the rear footpads,
and draining LNs were collected 1 hr and 10 min later,
respectively, for evaluation of the fluorescent tracer.
Data were compiled from two independent experiments
with n = 3–5 per group. *p < 0.05. Data are shown as
mean ± SEM.
See also Figure S5.
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Lymphatics Are Critical for Cholesterol Clearanceand active process—namely, HDL entry through lymphatic
vessels is mediated via SR-BI. This scavenger receptor is ubiq-
uitously expressed in several organs, and its function in choles-
terol metabolism is determined by the cell type. In the blood
vessels, endothelial SR-BI has been shown to actively transport
HDL from the vessel lumen into the peripheral tissues (Rohrer
et al., 2009). In the intestines, SR-BI on enterocytes is involved
in cholesterol uptake/binding, which could facilitate subsequent
cholesterol absorption via NPC1L1 (Labonte´ et al., 2007). In the
liver, hepatocyte SR-BI is important for the selective uptake of
esterified and unesterified cholesterol carried by HDL (Zhang
et al., 2005). Here, we demonstrate both in vitro and in vivo
that SR-BI is expressed by lymphatic endothelium andmediates
the internalization and transport of HDL. Although passive entry
into the lymphatic vessels may also contribute to HDL transport,
inhibition or absence of SR-BI markedly reduced in vivo the
transport of HDL from the interstitium to the draining LNs and
RCT, demonstrating that entry of interstitial HDL through
lymphatic vessels depends on SR-BI and probably outweighs
passive entry. Furthermore, since the loss of SR-BI activity had
no apparent effect on the transport of the macromolecule
TRITC-dextran both in vivo and in vitro and was not compen-
sated by the presence of ABCA1 expressed by lymphatic endo-
thelial cells, these findings further support the specific function of
SR-BI in lymphatic endothelium for the uptake of HDL. We next
addressed whether the transport of cholesterol through lym-
phatics involves the intercellular pathway, currently considered
to be the major pathway (Schmid-Scho¨nbein, 1990) or the
transendothelial pathway. This latter pathway, which has been
recently proposed as an additional pathway for the entry of mac-
romolecules in lymphatic vessels, may be mediated by vesicles,
which are abundant in lymphatic endothelium (Leak, 1976; Pod-
grabinska et al., 2002). Supporting this possible mechanism,
tracer particles injected in the interstitium of animals have been
identified within the vesicles of initial lymphatic vessels (Feng
et al., 2002; Leak, 1976). Our study on the transport of dual
labeled HDL through a monolayer of LECs reveals that the trans-
port of both the protein and lipid component of HDL involves, at
least in part, the transendothelial pathway and SR-BI, suggest-
ing that unlike on hepatocytes, SR-BI on LECs does not selec-
tively uptake cholesterol carried by HDL.
Here, we show that the structural alterations in lymphatic ves-
sels of apoE/mice are associated with the decreased expres-
sion of FOXC2 and VEGF-C. Furthermore, improvement of
lymphatic function in apoE/mice by reduction of hypercholes-
terolemia with ezetimibe markedly decreased cholesterol accu-
mulation and edema in peripheral tissues of these mice. These
data further support this two-way relationship between choles-
terol homeostasis and lymphatic function that we proposed pre-
viously (Lim et al., 2009) and demonstrate the essential role of
lymphatic drainage in controlling the clearance of cholesterol in
peripheral tissues. The decrease in cholesterol accumulation
observed in the skin of apoE/ mice treated with ezetimibe
may result from both a decreased influx of cholesterol in the
tissue as ezetimibe reduces total plasma cholesterol and an
increased clearance of interstitial cholesterol by lymphatic drain-
age. However, our experiment in which apoE/ mice were
treated locally with VEGF-C revealed that restoring lymphatic
function independently of lowering cholesterolemia can be suffi-Ccient to reduce the accumulation of cholesterol in the skin of
apoE/mice by supporting RCT. Taken together, these studies
in apoE/mice have direct clinical relevance and potential ther-
apeuticapplications. Indeed, theaccumulationof lipid in skin from
apoE/ mice as characterized by massive infiltration of lipid-
ladenmacrophagescorresponds toa clinical skin feature, namely
xanthoma (Frankel and Capone, 1995; van Ree et al., 1995).
Several clinicians proposed that poor lymphatic drainage may
further contribute to the formation of xanthomas (Berger et al.,
1972;Hunter et al., 1970;Polano,1969). Thisassociationbetween
poor lymphatic drainage and xanthomas was further strength-
ened by clinical studies reporting that the use of compression
garments to resolve lymphedema ameliorate xanthomatous
eruptions in these normolipidemic patients (Berger et al., 1972).
Notably, about half of the patients with xanthomas have primary
or secondary lipid disorders, and the presence of xanthomas
often serves as an important basic criterion in the clinical diag-
nosis of primary dyslipidemia, such as familial hypercholesterole-
mia (Goldberg et al., 2011; Frankel and Capone, 1995). However,
it remains unknown whether the interconnection between
lymphatic dysfunction and xanthomas formation also holds in
patients with dyslipidemia. Our data showing that restoration of
lymphatic vessel function in dyslipidemic apoE/mice with eze-
timibe decreased xanthomas supports this concept andprovides
strong evidence for the beneficial effect of improving lymphatic
drainage in patientswith xanthomaswith or without dyslipidemia.
Moreover, our data revealing that the structural and functional
defects in lymphatics from apoE/ mice were associated with
decreased expression of FOXC2 are in strong agreement with a
recent clinical study in patients with familial combined hyperlipid-
emia. Indeed, these dyslipidemic patients exhibited alterations in
lymphatic vessels and lower gene expression of FOXC2 and
Prox-1 in their adipose tissues (Horra et al., 2009)$
In conclusion, we provide direct evidence for the implication of
lymphatic vessels in the initial steps of RCT and that lymphatic
transport of cholesterol is an active process involving SR-BI.
These findings reveal lymphatic vessels as potential targets for
lipid-related diseases, including atherosclerosis, diabetes, and
familial hypercholesterolemia, and thus the need for increased
research on lymphatic function and lipid metabolism.
EXPERIMENTAL PROCEDURES
Cells and Mice
SV-LECs provided by Dr. J.S. Alexander were cultured as previously
described (Ando et al., 2005). Primary human dermal LEC and RAW264.7mac-
rophages were purchased from Lonza Australia (Mount Waverly, VIC,
Australia) and ATCC, respectively. ApoE/, Ldlr/, and SR-BI+/ mice on a
C57BL/6 background were obtained from Jackson Laboratory (Bar Harbor,
ME), fed different diet and treated in some experiments with ezetimibe or
VEGF-C as described in the Supplemental Experimental Procedures. All
experiment procedures were approved by the institutional animal care and
use committees of the National University of Singapore.
Lymphatic Functional Assessment
Lymphatic function was assessed using Evans blue dye for tracing cutaneous
lymphatic vessels as described previously (Lim et al., 2009).
Dendritic Cell Migration Assay
Migration of dendritic cell to LN was evaluated after epicutaneous application
of FITC solution as described previously (Angeli et al., 2004).ell Metabolism 17, 671–684, May 7, 2013 ª2013 Elsevier Inc. 681
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Whole-mount immunohistochemical analysis of the ear skin to visualize initial
and collecting lymphatic vessels was performed as described previously (Lim
et al., 2009). For analysis of the expression of SR-BI on mouse tail skin, spec-
imenswere fixed in 2%paraformaldehyde (PFA) and 30%sucrose overnight at
4C and frozen in Tissue-Tek Optimum Cutting Temperature compound for
10 mm cryosectioning. Immunostaining was performed with a Tyramide signal
amplification kit (Perkin Elmer) according to manufacturer’s instruction and
with rabbit anti-mouse SRB1 (rabbit polyclonal; Novus Biologicals) revealed
with rabbit horseradish peroxidase followed by Cy3-conjuagted Tyramide.
Costaining with Syrian hamster anti-mouse podoplanin (clone 8.1.1; Develop-
mental Studies Hybridoma Bank) antibody followed by AF488-conjugated
secondary antibodies (Jackson Immunoresearch) was used to identify
lymphatic vessels. For SR-BI and ABCA1 staining on SV-LECs and RAWmac-
rophages cultured on glass coverslips, cells were fixed in 4% PFA for 10 min
followed by staining with Syrian hamster anti-podoplanin and rabbit anti-
mouse SRB1 or ABCA1 polyclonal antibodies (Novus Biologicals). For lipid
staining, cryosections of mouse footpad skin were stained with hematoxylin
and oil red O. For identification of foam cells, skin sections were stained
with macrophage marker CD68 (rat clone FA-11; Serotec) followed by oil red
O staining, which was visualized as pseudocolored red under the Texas Red
filter.
Specimens were viewed with a fluorescence wide field (Axio Imager.Z1,
Axioxam HRM camera; Carl Zeiss Micro Imaging, Jena, Germany) or confocal
microscope (Leica TCS SP5; Leica Microsystems, Deerfield, IL) with LAS AF
confocal software (version 1.8.2; Leica Microsystems). Morphometric mea-
surements of initial lymphatic vessel diameter were performed as previously
described with Image J (Lim et al., 2009).
Disruption of Lymphatic Flow
A solution of 1% Evans Blue (Sigma) was injected into the hind-limb
footpads for visualization of lymphatic vessels. In the ‘‘surgical-operated’’
animal group, at least a 2 mm length of afferent lymphatic vessels draining
the popliteal LN was surgically cut (Ikomi et al., 2008), while lymphatic
vessels in the ‘‘sham-operated’’ animal group were left exposed in the
same way but not cut. Mice were used 12–21 days later for HDL uptake
and RCT.
Reverse Cholesterol Transport
22-NDB-cholesterol, a fluorescent analog of cholesterol (Molecular Probes),
was the preferred choice for our study because its uptake and efflux by/
from macrophages closely resemble that of radiolabeled cholesterol (Lamant
et al., 2006; Sparrow et al., 1999). We adapted the RCT protocol developed
by the laboratory of Rader (Wang et al., 2007; Zhang et al., 2003).
RAW264.7 macrophages were treated overnight with 5 mg/ml 22-NDB choles-
terol, and cholesterol efflux was evaluated as described in the Supplemental
Experimental Procedures. Mice received intraperitoneal or footpad subcu-
taneous injection of 0.5 ml or 20 ml, respectively, of 5 3 106 22-NDB-choles-
terol loaded macrophages. The footpads, blood, lymph, LNs, and liver were
collected 5 min and 12, 24, 48, and 72 hr later, whereas feces were collected
continuously from 24–48 and 48–72 hr later. Samples were then processed as
described in the Supplemental Experimental Procedures to measure choles-
terol fluorescence. Data were expressed as fluorescence intensity per mg of
tissue weight. Samples frommice receiving injection of noncholesterol loaded
macrophages were used as blanks.
In Vitro and In Vivo SR-BI Blockade
SR-BI was block in vitro and in vivo with the chemical inhibitor BLT1 (Sigma-
Aldrich) or a specific blocking antibody (Novus Biological, NB400-113) at
doses known to be effective. The effect of blocking SR-BI on RCT, HDL, and
FITC-dextran transport was evaluated as described in the Supplemental
Experimental Procedures.
In Vivo and In Vitro Lymphatic Uptake of HDL
To assess HDL transport in vivo or its uptake by SV-LECs or human LECs
in vitro, we used Dil-HDL (Biomedical Technologies) that was further labeled
with Alexa 488 (Molecular Probes kit) for some experiments or reconstituted
Alexa-488-labeled HDL (rHDL; containing 1-palmitoyl-2-linoleoylphosphati-682 Cell Metabolism 17, 671–684, May 7, 2013 ª2013 Elsevier Inc.dylcholine and apolipoprotein A-I prepared by cholate dialysis) as described
in the Supplemental Experimental Procedures.
HDL Transport through SV-LEC or Human LEC Monolayer
SV-LECs and human LECs were cultured on polyester membrane transwell
cell culture inserts (0.4 mm, Corning, NY) coated with collagen type I (BD, North
Ryde, NSW, Australia). In some experiments, cells were preincubated with
anti-SRB1 antibody, diluted 1/100 in serum-free media for 1 hr. For experi-
ments with SV-LECs, Dil-HDL was further labeled with an Alexa 488 protein
labeling kit (Invitrogen), and 30 mg/ml on this dual-labeled HDL or FITC dextran
was added on top of SV-LEC inserts for 1 hr at 37C or 4C. For experiments
with human LECs, cells were incubated with rHDL consisting of Alexa-488-
labeled apolipoproteinA-I (final concentration 10 mg/ml) for 10 min at 37C.
Then, 100 ml medium from the bottom well was removed for quantification of
the fluorescence signal (excitation 490 nm, emission 520 nm).
Quantitative Real-Time PCR
Real-time PCR was performed with SYBR Green PCR Master Mix (Applied
Biosystems) and analyzed on an Abi Prism 7500 Detection System (Applied
Biosystems, Warrington, UK) or the CFX96 Real-Time PCR detection system
(Bio-Rad) for mouse and human samples, respectively. The primers used
are listed in Table S1.
Small Interfering RNA Transfection
For silencing of ABCA1 or SRB1, amixture containing small interfering RNA for
ABCA1 (100 nM), SRB1 (100 nM), or AllStars negative control (50 nM or
100 nM; QIAGEN) and DMEMwithout serum and HiPerfect (QIAGEN) was pre-
pared for the transfection performed according to the manufacturer’s protocol
(QIAGEN). Transfection efficiency of SV-LECs was analyzed as described in
the Supplemental Experimental Procedures.
Flow-Cytometric Analysis of SR-BI and ABCA1 Expression
SV-LECs and RAW cells and primary lymphatic endothelial cells from mouse
ear skin isolated as described in the Supplemental Experimental Procedures,
were stained with rabbit anti-mouse ABCA1 or SR-BI followed by anti-rabbit
APC. FACS analysis was performed with a CyAn ADP Analyzer (Beckman
Coulter) and data were analyzed with Flowjo software (Treestar).
Statistical Analysis
Statistical Analysis was performed with Graphpad Prism version 5.0
(GraphPad Software). All the data were presented as mean ± SEM and were
statistically analyzed by nonparametric Mann-Whitney U test. A p value of
less than 0.05 was considered to be statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.cmet.2013.04.002.
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